Assenagon Asset Management SA owns $244,000 in Neuronetics, Inc. (NASDAQ:STIM)

Assenagon Asset Management SA increased its holdings in Neuronetics, Inc. (NASDAQ:STIM – Free Report) by 63.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 135,746 shares of the company’s stock after purchasing an additional 52,450 shares during the period. Assenagon Asset Management SA’s holdings in Neuronetics were worth $244,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of STIM. Fielder Capital Group LLC acquired a new stake in shares of Neuronetics in the 4th quarter valued at $66,000. Thompson Siegel & Walmsley LLC purchased a new stake in shares of Neuronetics in the 4th quarter valued at $545,000. Worth Venture Partners LLC purchased a new stake in shares of Neuronetics in the 4th quarter valued at $30,000. Millrace Asset Group Inc. boosted its stake in Neuronetics by 205.1% in the fourth quarter. Millrace Asset Group Inc. now owns 725,369 shares of the company’s stock valued at $2,104,000 after buying an additional 487,591 shares during the last quarter. Finally, G2 Investment Partners Management LLC bought a new position in Neuronetics in the 4th quarter worth $213,000. Institutional investors and hedge funds own 53.59% of the company’s shares.

Neuronetics stock performance

Shares of STIM stock opened at $0.97 on Friday. The company’s fifty-day moving average price is $1.66 and its 200-day moving average price is $2.75. Neuronetics, Inc. it has a one year low of $0.66 and a one year high of $5.07. The company has a debt-to-equity ratio of 2.38, a current ratio of 2.58, and a quick ratio of 2.37. The company has a market cap of $29.24 million, a PE ratio of -1.01 and a beta of 2.32.

Neuronetics (NASDAQ:STIM – Get Your Free Report ) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.06). Neuronetics had a negative return on equity of 109.00% and a negative net margin of 45.06%. The company had revenue of $16.45 million for the quarter, compared to the consensus estimate of $18.76 million. In the same quarter last year, the firm posted EPS of ($0.17). As a group, analysts expect Neuronetics, Inc. to post -0.87 earnings per share for the current year.

Insider trading at Neuronetics

In related news, Director Robert Cascella purchased 50,000 shares of the business’s stock in a transaction dated Thursday, June 6th. The stock was bought at an average price of $2.05 per share, for a total transaction of $102,500.00. Following the acquisition, the director now owns 244,098 shares in the company, valued at approximately $500,400.90. The transaction was disclosed in a legal filing with the SEC, which is available via this hyperlink. In other news, CEO Keith J. Sullivan sold 24,162 shares of the business’s stock in a transaction dated Thursday, July 18th. The shares were sold at an average price of $1.90, for a total transaction of $45,907.80. Following the transaction, the chief executive officer now owns 1,324,354 shares in the company, valued at approximately $2,516,272.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC’s website. Also, Director Robert Cascella bought 50,000 shares of the business’s stock in a transaction dated Thursday, June 6th. The shares were acquired at an average price of $2.05 per share, for a total transaction of $102,500.00. Following the completion of the transaction, the director now owns 244,098 shares in the company, valued at approximately $500,400.90. Disclosure for this purchase can be found here. Over the last 90 days, insiders bought 124,000 shares of company stock worth $171,810. 9.80% of shares are currently owned by company insiders.

Analysts on Wall Street are forecasting an increase

Several research analysts recently commented on the stock. JMP Securities dropped their target price on shares of Neuronetics from $7.00 to $3.00 and set a “market outperform” rating on the stock in a report on Wednesday, August 14th. William Blair reiterated a “market perform” rating on shares of Neuronetics in a report on Monday, August 12th. Finally, Canaccord Genuity Group decreased their price target on shares of Neuronetics from $6.00 to $3.00 and set a “buy” rating on the stock in a report on Tuesday, August 13th.

Get the latest neuronetics stock report

Neuronetics Company Profile

(Free report)

Neuronetics, Inc, a commercial medical technology company, designs, develops and markets products for patients with neurohealth disorders in the United States and internationally. The company offers the NeuroStar Advanced Therapy System, a non-invasive, non-systemic office-based treatment to treat adult patients with major depressive disorder.

See Also

Want to see what other hedge funds own STIM? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for Neuronetics, Inc. (NASDAQ:STIM – Free Report).

Get news and reviews for Neuronetics daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Neuronetics and related companies with MarketBeat.com’s FREE daily email newsletter.